Spelling suggestions: "subject:"drugs - solubility"" "subject:"drugs - volubility""
1 |
Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticalsShefter, Eli. January 1963 (has links)
Thesis (Ph. D.)--University of Wisconsin--Madison, 1963. / Typescript. Abstracted in Dissertation abstracts, v. 23 (1963) no. 9, p. 3325-26. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 68-69).
|
2 |
Use of the combination of prodrug design and salt optimization - a strategy to enchance aqueous solubility of drugs /Bach Nielsen, Anders. January 2004 (has links)
Ph.D.
|
3 |
A nanoparticle engineering process: spray-freezing into liquid to enhance the dissolution of poorly water soluble drugsHu, Jiahui 28 August 2008 (has links)
Not available / text
|
4 |
Nanoparticle engineering processes: evaporative precipitation into aqueous solution (EPAS) and antisolvent precipitation to enhance the dissolution rates of poorly water soluble drugsChen, Xiaoxia 28 August 2008 (has links)
Not available / text
|
5 |
Big data analysis of solid dispersion researches from 1980 to 2015Zhang, Jing Lu January 2018 (has links)
University of Macau / Institute of Chinese Medical Sciences
|
6 |
SOLUBILIZATION OF SOME POORLY SOLUBLE DRUGS BY COSOLVENTS (FORMULATION, IDEALITY, POLARITY).RUBINO, JOSEPH THOMAS. January 1984 (has links)
The solubilities of three poorly water soluble drugs, phenytoin, diazepam and benzocaine, were measured in various cosolvent-water mixtures. The data were generally described by the relationship: log (S(m)/S(w)) = Σf₁σ₁ where S(m) is the solubility of the drug in the cosolvent-water mixture, S(w) is the solubility of the drug in water, f₁ is the volume fraction of cosolventi and σ₁ is the slope of the log(S(m)/S(w)) vs. f₁ plot. In most cases, some positive or negative deviation from the log-linear solubility equation is observed. The deviation is similar for all three drugs in many of the cosolvent-water mixtures. This suggests that the deviation is primarily due to interactions between the solvent components. However, it could not be predicted from any of the physical properties of the solvent mixtures. Changes in the solute crystal structure could not be identified as a source of nonideality. The deviations from the log-linear solubility equation may involve such factors as changes in solvent structure, hydrophobic hydration, density changes and hydrogen bonding differences between solute and cosolvent. The slopes, σ₁, of the solubilization plots were related to various indexes of solvent polarity including dielectric constant, solubility parameter, partition coefficient, surface tension and interfacial tension. The best correlations were obtained with measures of solvent cohesive forces such as interfacial tension and solubility parameter. In general, the solubilities in mixtures of aprotic cosolvents and water are higher than predicted by any of the polarity indexes. The slopes are thus related to the hydrogen bonding ability of the cosolvent as expressed by the density of proton donor and acceptor groups of the neat cosolvent. The slopes of the solubilization plots can be predicted from linear relationships with polarity indexes of the cosolvent. Therefore it is possible to estimate the slope, σ, in any cosolvent-water mixture from the solubilities in two solvents for a given drug. Furthermore, the solubility in any cosolvent water mixture can be estimated by combining the log-linear solubility equation with the estimated slopes.
|
7 |
Dense gas particle processing for alternative drug delivery formulationsTandya, Andrian, Chemical Sciences & Engineering, Faculty of Engineering, UNSW January 2006 (has links)
Pulmonary and oral drug administrations are usually the preferred methods of delivery of active pharmaceutical ingredients.Generally,pulmonary drug formulations are more attractive compared to oral formulations since they consist of micron-sized powders with high surface area thus having faster onset of action,as well as minimizing the drug dosage and side effects.Oral insulin formulations,if achievable,would provide an alternative to injectable insulin,as the common drawbacks of injectable insulin are the multiple daily injections and the possibility of skin infections at the injection site. In this study,the feasibility of using dense gas particle processing techniques known as the Aerosol Solvent Extraction System (ASES),Gas Anti-Solvent (GAS)and High-Pressure Media Milling (HPMM)for pharmaceutical processing was assessed.The ASEStechnique,utilizing dense ethane,was employed to prepare insulin-lactose formulations for pulmonary administration whilst the GAS and ASES techniques,utilizing dense CO2,were employed to prepare microencapsulated formulations containing insulin and Eudragit?? S100 for oral administration.Furthermore,the HPMM technique,utilizing dense hydrofluocarbon (HFC)134a/227ea,was employed to prepare suspension Metered Dose Inhaler (MDI)formulations containing budesonide and various surfactants. The Fine Particle Fraction (FPF)of processed insulin without the presence of lactose was found to be 44%.In other words,44% of processed insulin delivered to the impactor stages (excluding the throat and neck)has aerodynamic diameter of less than 5??m.With the addition of lactose as carrier,the FPFof the insulin-lactose (1:1w/w)formulation increased to 64%.The increase in FPFwas attributed to the lower density of lactose particles compared to that of insulin particles to produce an intimate mixture with enhanced powder flowability and aerodynamic performance. Proteins for oral delivery should ideally be formulated with acid-resistant polymer as a protective coating to protect against enzymatic degradation in the stomach.Eudragit?? S100,which is insoluble or almost impermeable at pH 1-4and soluble at pH 5-7,was used to prepare oral insulin formulations.The insulin release at pH 3was sustained by the Eudragit?? S100coating and the encapsulation efficiency of insulin??Eudragit?? S100formulations varied between 6% and 24% depending on the initial drug to polymer ratio. One of the major therapies utilizing metered dose inhaler formulations in the treatment of asthma has been studied using the HPMM process.The HPMM process has been demonstrated to be an efficient milling process for the enhancement of the physical stability and aerodynamic performance of budesonide in HFC-134a/227ea propellant formulations.No significant change in physical stability was observed in the formulations for 2 weeks.
|
8 |
Recrystallization of guaifenesin from hot-melt extrudates containing Acryl-EZE® or Eudragit® L100-55Bruce, Caroline Dietzsch, 1976- 29 August 2008 (has links)
The physical stability of guaifenesin in melt-extruded acrylic matrix tablets was investigated. The initial study found that recrystallization was caused by guaifenesin supersaturation in Eudragit[Trademark] L100-55, and that the instability was confined to tablet surfaces. Drug release was not affected by crystal growth as guaifenesin is very water soluble. The addition of a polymer in which guaifenesin showed a higher solubility to the matrix blend decreased recrystallization on storage as supersaturation levels dropped. The second investigation identified heterogeneous nucleation as an additional factor in guaifenesin recrystallization. A quantitative assay showed that talc in matrix tablets accelerated the onset and extent of the recrystallization due to a nucleating effect on guaifenesin. Storage under elevated humidity conditions promoted recrystallization as well, but crystal growth was not correlated with water uptake, which implied a nucleating effect of moisture on guaifenesin. The third study investigated the effect of aqueous film-coating of the matrix tablets to stabilize amorphous guaifenesin using either hypromellose or ethylcellulose as coating polymers. The selection of the coating polymer influenced crystal morphology, and was a major factor in delaying the onset of crystallization, ranging from 1-3 weeks (ethylcellulose film-coatings) to 3-6 months (hypromellose film-coatings). Higher weight gains retarded recrystallization. Factors promoting drug and polymer diffusion, such as long curing times and elevated temperatures during both curing and storage, incomplete film coalescence and high core drug concentrations all resulted in an earlier onset of crystallization. The effects of single-screw extrusion (SSE) and twin-screw extrusion (TSE) of diltiazem hydrochloride and guaifenesin-containing blends in Eudragit[Trademark] L100-55 on drug morphology and dispersion were studied in the fourth project. Guaifenesin solubilized diltiazem hydrochloride, and plasticized Eudragit[Trademark] L100-55. Extrusion temperature influenced the drug morphology in single-screw extrudates, while TSE rendered all formulations amorphous due to higher dispersive mixing capabilities. Drug distribution improved with extrusion temperature and by TSE over SSE. Homogeneous matrices showed the slowest drug release at pH 1.0. Recrystallization was inversely correlated to drug distribution. In conclusion, the physical stability of guaifenesin in hot melt-extruded acrylic matrix tablets was shown to be affected by formulation, processing and post-processing factors. / text
|
9 |
Dense gas particle processing for alternative drug delivery formulationsTandya, Andrian, Chemical Sciences & Engineering, Faculty of Engineering, UNSW January 2006 (has links)
Pulmonary and oral drug administrations are usually the preferred methods of delivery of active pharmaceutical ingredients.Generally,pulmonary drug formulations are more attractive compared to oral formulations since they consist of micron-sized powders with high surface area thus having faster onset of action,as well as minimizing the drug dosage and side effects.Oral insulin formulations,if achievable,would provide an alternative to injectable insulin,as the common drawbacks of injectable insulin are the multiple daily injections and the possibility of skin infections at the injection site. In this study,the feasibility of using dense gas particle processing techniques known as the Aerosol Solvent Extraction System (ASES),Gas Anti-Solvent (GAS)and High-Pressure Media Milling (HPMM)for pharmaceutical processing was assessed.The ASEStechnique,utilizing dense ethane,was employed to prepare insulin-lactose formulations for pulmonary administration whilst the GAS and ASES techniques,utilizing dense CO2,were employed to prepare microencapsulated formulations containing insulin and Eudragit?? S100 for oral administration.Furthermore,the HPMM technique,utilizing dense hydrofluocarbon (HFC)134a/227ea,was employed to prepare suspension Metered Dose Inhaler (MDI)formulations containing budesonide and various surfactants. The Fine Particle Fraction (FPF)of processed insulin without the presence of lactose was found to be 44%.In other words,44% of processed insulin delivered to the impactor stages (excluding the throat and neck)has aerodynamic diameter of less than 5??m.With the addition of lactose as carrier,the FPFof the insulin-lactose (1:1w/w)formulation increased to 64%.The increase in FPFwas attributed to the lower density of lactose particles compared to that of insulin particles to produce an intimate mixture with enhanced powder flowability and aerodynamic performance. Proteins for oral delivery should ideally be formulated with acid-resistant polymer as a protective coating to protect against enzymatic degradation in the stomach.Eudragit?? S100,which is insoluble or almost impermeable at pH 1-4and soluble at pH 5-7,was used to prepare oral insulin formulations.The insulin release at pH 3was sustained by the Eudragit?? S100coating and the encapsulation efficiency of insulin??Eudragit?? S100formulations varied between 6% and 24% depending on the initial drug to polymer ratio. One of the major therapies utilizing metered dose inhaler formulations in the treatment of asthma has been studied using the HPMM process.The HPMM process has been demonstrated to be an efficient milling process for the enhancement of the physical stability and aerodynamic performance of budesonide in HFC-134a/227ea propellant formulations.No significant change in physical stability was observed in the formulations for 2 weeks.
|
10 |
Dissolution control of highly soluble active pharmaceutical ingredients via cocrystallisationNyamayaro, Kudzanai January 2017 (has links)
Thesis (MTech (Chemistry))--Cape Peninsula University of Technology, 2017. / Crystal engineering involves the manipulation of intermolecular interactions to design
functionalised crystalline materials and has proved to be an effective tool for the modification
of physicochemical properties of active pharmaceutical ingredients (APIs). In the first section
of this study, the aim was to systematically influence the rate of dissolution of a highly soluble
active pharmaceutical ingredient using crystal engineering principles.
Salicylic acid (SA) was employed as a model API to form multicomponent crystals with a series
of selected cinchona alkaloids, namely quinine (QUIN), quinidine (QUID), cinchonine (CINC),
cinchonidine (CIND), N-benzylquininium chloride (NBQUIN), N-benzylcinchonidinium chloride
(NBCIND) and N-benzylcinchoninium chloride (NBCINC). The resulting novel crystalline forms
were found to be salts, and were characterised using single crystal X-ray diffraction, powder
X-ray diffraction, differential scanning calorimetry and thermogravimetric analysis. The
dissolution profiles of the salicylate salts, measured from an aqueous media using high
performance liquid chromatography-mass spectroscopy, show a significant decrease in the
rate of dissolution of SA. Subsequently, Hirshfeld surface analysis was used as a tool for
quantitative and qualitative comparison of the crystal structures. This study indicates that the
rate of dissolution can be successfully influenced by methodically adding extra hydrophobic
groups onto the coformer.
In the second section, we applied the information obtained from the SA studies to
acetylsalicylic acid (aspirin, ASA). We sought to improve its thermal stability and dissolution
via the formation of new solid forms with the aforementioned cinchona alkaloids. We
successfully synthesized a novel drug-drug salt of an analgesic, non-steroidal antiinflammatory
and antipyretic drug (ASA), and an antimalarial and analgesic drug (QUIN). The
salt was formed both by using solution methods and liquid assisted grinding - a green
chemistry technique. The salt exhibited physicochemical properties different from the parent
drugs, and a reduced rate of dissolution. / National Research Foundation(NRF)
|
Page generated in 0.0659 seconds